Stay updated on CABozantinib in NSCLC MET Clinical Trial
Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.5.2 was added and v3.5.0 was removed. This maintenance update does not modify study content.SummaryDifference0.0%

- Check18 days agoChange DetectedPadova, PD, Italy 35128 has been added and Padua, PD, Italy 35128 removed from the locations list.SummaryDifference0.0%

- Check33 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check47 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check76 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding notice and the prior Revision: v3.4.1.SummaryDifference0.3%

- Check83 days agoChange DetectedThe page now displays a site-wide funding status notice and has a version update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.